Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing

Clin Pharmacol Ther. 2013 Feb;93(2):153-8. doi: 10.1038/clpt.2012.209. Epub 2012 Oct 17.

Abstract

Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B*58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.

Publication types

  • Practice Guideline
  • Research Support, N.I.H., Extramural

MeSH terms

  • Alleles
  • Allopurinol / administration & dosage*
  • Allopurinol / adverse effects
  • Dose-Response Relationship, Drug
  • Genotype
  • Gout / drug therapy
  • Gout Suppressants / administration & dosage*
  • Gout Suppressants / adverse effects
  • HLA-B Antigens / genetics*
  • Humans
  • Hyperuricemia / drug therapy
  • Pharmacogenetics
  • Stevens-Johnson Syndrome / chemically induced
  • Stevens-Johnson Syndrome / etiology
  • Stevens-Johnson Syndrome / genetics*

Substances

  • Gout Suppressants
  • HLA-B Antigens
  • HLA-B*58:01 antigen
  • Allopurinol